On May 30th, international experts and politicians gathered in Leiden to discuss global health issues. Lively discussions were held on matters concerning equal worldwide access to vaccines and diversity within clinical research. New scientific insights were also shared, including on vaccine response differences between African and European populations. The daily conclusion was clear: global collaboration and innovative research is key to solving the greatest health challenges of our time.
During the Global Impact in Health Symposium forces were joined with Leiden University, Health~Holland, Bristol Myers Squibb (BMS), Janssen, Philips and the Leiden Bio Science Park (LBSP). The aim was to bring together international experts and to stimulate new collaborations. Experts not only came from all over the world, but also from different branches, such as academia, politics, public or private sector.
This mix of high-level people and expert led to vivid discussion on the major challenges in global health(care). Read the full story here!
The African-European Tuberculosis Consortium (AE-TBC) is an international multisite group of African and European researchers who investigate the use of host biosignatures for the diagnosis of active TB disease. For over ten years, the LUMC groups of Infectious Diseases and Cell & Chemical Biology from Prof Annemieke Geluk and Dr Paul Corstjens respectively, have been partners of the EDCTP consortia for tuberculosis (among which AE-TBC). The AE-TBC recently won the prize for ‘Outstanding Research Team 2020, awarded by the EDCTP.
The Janssen-Cilag International N.V COVID-19 vaccine has received authorization for emergency use by the European Medicines Agency (EMA) on March 11. Developed with fundamental support from the Molecular Virology group of the Leiden University Medical Centre (LUMC), it is the fourth vaccine to be administered in the European Union. The Netherlands has ordered more than 11 million vaccine doses.
“This is an achievement in alignment with the mission of VODAN-Africa to generate continuous, real-time, high velocity clinical observational patient data from resource-limited communities that have not been well represented in digital health data. The key feature is that the data produced remains in the health facility only. It will not leave the health facility. Since the data is machine-actionable the input of the data only happens once; in the deployable architecture, the data is used for four parallel use cases” (VODAN to Africa, 2022).